7 results on '"Durlik K"'
Search Results
2. Recent advances on smart glycoconjugate vaccines in infections and cancer
- Author
-
Anderluh, M, Berti, F, Bzducha-Wrobel, A, Chiodo, F, Colombo, C, Compostella, F, Durlik, K, Ferhati, X, Holmdahl, R, Jovanovic, D, Kaca, W, Lay, L, Marinovic-Cincovic, M, Marradi, M, Ozil, M, Polito, L, Reina, JJ, Reis, CA, Sackstein, R, Silipo, A, Svajger, U, Vanek, O, Yamamoto, F, Richichi, B, van Vliet, SJ, RTEÜ, Fen - Edebiyat Fakültesi, Kimya Bölümü, and Özil, Musa
- Subjects
Glycosylation ,Immune system ,Vaccination ,Infection ,Cancer - Abstract
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as "tumor-associated carbohydrate antigens". Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy. European Cooperation in Science and Technology (COST) CA18103 Ministry of Education, Youth & Sports - Czech Republic CA18103 LTC20078
- Published
- 2021
3. Emerging glyco-based strategies to steer immune responses
- Author
-
Robert Sackstein, Barbara Richichi, Marco Marradi, Alba Silipo, Milena Marinović-Cincović, Wiesław Kaca, Francesco Berti, Urban Švajger, Ondřej Vaněk, Rikard Holmdahl, Sandra J. van Vliet, Fabrizio Chiodo, Katarzyna Durlik, Celso A. Reis, Dragana Jovanovic, Marko Anderluh, Xhenti Ferhati, Josè Juan Reina-Martin, Anna Bzducha-Wróbel, Luigi Lay, Fumiichiro Yamamoto, Laura Polito, Musa Özil, Federica Compostella, Cinzia Colombo, RTEÜ, Fen - Edebiyat Fakültesi, Kimya Bölümü, Özil, Musa, Molecular cell biology and Immunology, AII - Cancer immunology, CCA - Cancer biology and immunology, Anderluh, M., Berti, F., Bzducha-Wrobel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik, K., Ferhati, X., Holmdahl, R., Jovanovic, D., Kaca, W., Lay, L., Marinovic-Cincovic, M., Marradi, M., Ozil, M., Polito, L., Reina-Martin, J. J., Reis, C. A., Sackstein, R., Silipo, A., Svajger, U., Vanek, O., Yamamoto, F., Richichi, B., and van Vliet, S. J.
- Subjects
0301 basic medicine ,Glycan ,glycosylation ,medicine.medical_treatment ,T-Lymphocytes ,Context (language use) ,Computational biology ,Cell Communication ,Biology ,Biochemistry ,Epitope ,Immune tolerance ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Nanoparticle ,Antigen ,Polysaccharides ,medicine ,cancer ,Animals ,Humans ,Polysaccharide ,Molecular Biology ,Receptors, Chimeric Antigen ,Animal ,autoimmunity ,Emerging Methods and Technologies ,Cell Biology ,Immunotherapy ,Glycans, C-type lectins, Immunotherapy ,vaccination ,Chimeric antigen receptor ,3. Good health ,carbohydrates (lipids) ,immune system ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Nanoparticles ,Protein Processing, Post-Translational ,Human - Abstract
Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell–cell communications and in the regulation of immune responses. Through the interaction with glycan‐binding receptors, glycans are able to affect the activation status of antigen‐presenting cells, leading either to induction of pro‐inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco‐chemists and glyco‐immunologists to develop glycan‐based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review, we highlight emerging advances in this field, and in particular, we discuss on how glycan‐modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen‐presenting cells, like dendritic cells. In addition, we address how glycan‐based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan‐based therapies, including chimeric antigen receptor (CAR)‐T cells to achieve targeting of tumor‐associated glycan‐specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity., Glycans are macromolecules that perform crucial roles in development, in cell–cell communication, and in the regulation of immune responses. In this review, we highlight how glycans can be exploited and empowered as treatment or vaccine modalities, particularly in the fight against cancer and autoimmune diseases.
- Published
- 2021
- Full Text
- View/download PDF
4. Recent advances on smart glycoconjugate vaccines in infections and cancer
- Author
-
Musa Özil, José J. Reina, Fabrizio Chiodo, Barbara Richichi, Ondřej Vaněk, Katarzyna Durlik, Cinzia Colombo, Sandra J. van Vliet, Alba Silipo, Federica Compostella, Anna Bzducha-Wróbel, Xhenti Ferhati, Francesco Berti, Milena Marinović-Cincović, Robert Sackstein, Rikard Holmdahl, Luigi Lay, Fumiichiro Yamamoto, Dragana Jovanovic, Marko Anderluh, Wiesław Kaca, Urban Švajger, Marco Marradi, Celso A. Reis, Laura Polito, Anderluh, M., Berti, F., Bzducha-Wrobel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik, K., Ferhati, X., Holmdahl, R., Jovanovic, D., Kaca, W., Lay, L., Marinovic-Cincovic, M., Marradi, M., Ozil, M., Polito, L., Reina, J. J., Reis, C. A., Sackstein, R., Silipo, A., Svajger, U., Vanek, O., Yamamoto, F., Richichi, B., and van Vliet, S. J.
- Subjects
0301 basic medicine ,glycosylation ,Biochemistry ,Immunoglobulin G ,Virus ,Epitope ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antigen ,Immunity ,Polysaccharides ,Neoplasms ,medicine ,cancer ,Humans ,Molecular Biology ,Vaccines ,biology ,business.industry ,SARS-CoV-2 ,Cancer ,COVID-19 ,Cell Biology ,medicine.disease ,vaccination ,infection ,3. Good health ,Vaccination ,immune system ,030104 developmental biology ,030220 oncology & carcinogenesis ,Immunology ,biology.protein ,business ,Glycoconjugates - Abstract
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor-associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
- Published
- 2021
- Full Text
- View/download PDF
5. Recent advances on smart glycoconjugate vaccines in infections and cancer.
- Author
-
Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, Durlik K, Ferhati X, Holmdahl R, Jovanovic D, Kaca W, Lay L, Marinovic-Cincovic M, Marradi M, Ozil M, Polito L, Reina JJ, Reis CA, Sackstein R, Silipo A, Švajger U, Vaněk O, Yamamoto F, Richichi B, and van Vliet SJ
- Subjects
- Glycoconjugates therapeutic use, Humans, Polysaccharides therapeutic use, SARS-CoV-2, COVID-19 prevention & control, Neoplasms prevention & control, Vaccines
- Abstract
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as "tumor-associated carbohydrate antigens". Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy., (© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2022
- Full Text
- View/download PDF
6. Emerging glyco-based strategies to steer immune responses.
- Author
-
Anderluh M, Berti F, Bzducha-Wróbel A, Chiodo F, Colombo C, Compostella F, Durlik K, Ferhati X, Holmdahl R, Jovanovic D, Kaca W, Lay L, Marinovic-Cincovic M, Marradi M, Ozil M, Polito L, Reina-Martin JJ, Reis CA, Sackstein R, Silipo A, Švajger U, Vaněk O, Yamamoto F, Richichi B, and van Vliet SJ
- Subjects
- Animals, Cell Communication immunology, Humans, Nanoparticles chemistry, Polysaccharides chemistry, Protein Processing, Post-Translational, Autoimmunity immunology, Polysaccharides immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell-cell communications and in the regulation of immune responses. Through the interaction with glycan-binding receptors, glycans are able to affect the activation status of antigen-presenting cells, leading either to induction of pro-inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco-chemists and glyco-immunologists to develop glycan-based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review, we highlight emerging advances in this field, and in particular, we discuss on how glycan-modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen-presenting cells, like dendritic cells. In addition, we address how glycan-based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan-based therapies, including chimeric antigen receptor (CAR)-T cells to achieve targeting of tumor-associated glycan-specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity., (© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2021
- Full Text
- View/download PDF
7. Characterization of Proteus mirabilis Lipopolysaccharide Samples by Infrared Spectroscopy and Serological Methods.
- Author
-
Durlik K, Czerwonka G, Żarnowiec P, and Kaca W
- Subjects
- Enzyme-Linked Immunosorbent Assay, Lipopolysaccharides immunology, Proteus mirabilis immunology, Serology, Spectrophotometry, Infrared, Antibodies, Bacterial metabolism, Lipopolysaccharides isolation & purification, Proteus mirabilis metabolism
- Abstract
Methods of lipopolysaccharide extraction, purification, and sample validation are presented. Based on serological reaction in ELISA, immunoblotting, and infrared spectra, identities of two LPS preparations from smooth P. mirabilis (O18) PrK 34/57 are presented.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.